PT - JOURNAL ARTICLE AU - J. Fernández-Lahera AU - S. Rojas AU - M. Lerin AU - D. Barros AU - A. Mendieta AU - D. Romera AU - J. Fernández-Bujarrabal AU - B. Ortega AU - R. Alvarez-Sala TI - Changes in lung function and comorbidity in patients with COPD over 4 to 10 years of follow-up DP - 2013 Sep 01 TA - European Respiratory Journal PG - P4184 VI - 42 IP - Suppl 57 4099 - http://erj.ersjournals.com/content/42/Suppl_57/P4184.short 4100 - http://erj.ersjournals.com/content/42/Suppl_57/P4184.full SO - Eur Respir J2013 Sep 01; 42 AB - OBJECTIVESTo study FEV1 evolution and analyse changes in comorbidity over a 4 to 10 year period in patients diagnosed with COPDMETHODSRetrospective study of demographic, spirometric and comorbidity variables of patients with COPD who were followed up for 4 to 10 years. We calculated the yearly change in prebronchodilator FEV1 and differences in comorbidity between the start (2001-2007) and end (2011-2012).RESULTSWe included 65 patients (91% men, 9% women, mean age 76±8 years, BMI, 28±4 kg/m2, FEV1% 59±19%). The follow-up time was 7±3 years. Air flow limitation (GOLD): 13% level I, 47% II, 32% III and 8% IV. The mean yearly decline in FEV1 was -26±51 ml. We classified patient decline according to the yearly percentile decline in FEV1 as follows: rapid decline (P75, 35±42 ml, 24%).We determined (ANOVA) that age, BMI, Charlson index and dyspnea (MRC) had no significant effect on FEV1 decline.The mean Charlson index (ChI) at the start was 1.07±1.02 (3.2±1.5 corrected for age), and the most recent mean ChI was 2.14±1.2 (5.22±1.7).Comorbidities: HBP 51%, dyslipidemia 38%, cardiac 30%, rheumatologic 25%, neurologic 16%, DM 14%, and neoplasms 12% (increased incidence of 10%, 12%, 10%, 11%, 4%, 3%, and 5%, respectively). Others: 34% respiratory failure, 12% OSAHS, nodules or lung cancer 13%, asthma 7%. There were no significant differences in comorbidities based on the pattern of FEV1 decline.CONCLUSIONThe change in FEV1 over the course of the study was heterogeneous. We were able to distinguish three patterns: rapid, slow and no decline.Comorbidities increased with time, with a difference of 1.07 points (1.99 corrected for age) in the Charlson index between the start and the end.